Let's look beyond the hype the company is generating this year.Could 2024 be a breakout year for Viking Therapeutics (VKTX -4.01%)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial clinical progress, Viking Therapeutics' shares have tripled this year.Biotech investors have noticed, but many remain on the sidelines wondering whether Viking is the right choice for them -- or whether the stock is a one-hit (or one-year) wonder. Let ...